Sofia Duran-Hernandez

Dr. Sofia Duran-Hernandez


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2025 in Toxins
Verified
Journal Article
Open access
PDF file
Sofia Duran-HernandezSofia Duran-Hernandez
Sofia Duran-Hernandez
NHNorma Estela Herrera-Gonzalez
Norma Estela Herrera-Gonzalez
NDNayar Durán-Hernández
Nayar Durán-Hernández
MCMartha Carnalla
Martha Carnalla
MLManuel de Jesus Castillejos López
Manuel de Jesus Castillejos López
CSCitlaltepetl Salinas-Lara
Citlaltepetl Salinas-Lara
Osteoarthritis (OA) is the most prevalent rheumatologic disease and a leading cause of years lived with disability worldwide. There are no disease-modifying drugs available to treat it. This study aimed to evaluate the effect of a single dose of 100U botulinum neurotoxin-A (BoNT-A) in patients with early knee OA. We designed a single-arm preliminary clinical trial in patients diagnosed with knee OA (KOA) grades I and II. 45 Patients received a single dose of 100U IncobotulinumtoxinA in the retro-patellar bursa and received nutritional and physical rehabilitation indications. Patients were evaluated at baseline and at days 5, 30, 60, and 90 after injection. The primary outcome was the reduction in pain using the visual analog scale (VAS). Knee function was evaluated using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). We assessed secondary adverse effects and measured muscular strength in every consultation. Descriptive endpoint summaries and a generalized linear random-effect model were used to evaluate changes in each follow-up time compared to baseline. IncobotulinumtoxinA treatment significantly (p < 0.001) reduced pain in all treated patients at day 90 compared to day 0. Patients showed a significant reduction in total WOMAC score (p < 0.001), from a mean baseline of 44.6 (95% CI; 41.4, 47.8) to 4.4 at day 90 (95% CI; 0.2, 0.3). Our results show that IncobotulinumtoxinA applied in the retro-patellar bursa is a safe and effective treatment for pain in patients with early-stage KOA, offering a potential alternative for symptomatic control in KOA.

30 June 2026 in Toxins
Verified
Journal Article
Open access
PDF file
JFJorge Hernández Franco¹
Jorge Hernández Franco¹
SMSalvador Jose Santamaría Molina
Salvador Jose Santamaría Molina
JSJosé J. Zorrilla Sánchez
José J. Zorrilla Sánchez
JRJorge Carranza - del Río
Jorge Carranza - del Río
IVIsrael Sánchez Villavicencio
Israel Sánchez Villavicencio
PVPedro Ivan Arias Vazquez
Pedro Ivan Arias Vazquez
Cervical dystonia and spasticity are debilitating neuromuscular disorders that substantially impair quality of life. Botulinum toxin type A (BoNT-A) is a cornerstone therapy; however, heterogeneity in dosing, muscle selection, and guidance techniques can limit outcomes, and Mexico-specific practical guidance is limited. We convened a multidisciplinary panel of Mexican rehabilitation and neurology specialists with extensive experience in BoNT-A injection; recommendations were developed through a three-phase process: a targeted literature search, a structured online survey of Mexican rehabilitation and neurology specialists, and an in-person meeting (21 February 2025) where clinicians reviewed aggregated survey results and refined practical recommendations through structured deliberation. The manuscript provides pragmatic guidance on evaluation and goal setting, muscle selection, working dilutions, dosing ranges, and reinjection intervals, emphasizing ultrasound (US) and/or electromyography (EMG) for deep or high-risk targets. It also summarizes key adverse events and proposes a stepwise approach to inadequate response, prioritizing reassessment of diagnosis, goals, targeting, and techniques before considering immunogenicity testing, product switching, or alternative interventions. These recommendations aim to improve standardization, safety, and goal attainment in routine Mexican practice.